Neutral, positive and negative APIs can effectively combine with sulfobutyl ether-β-Cyclodextrin 182410-00-0, which can increase the solubility of compounds with different solubility by 10 to 25000 times.
It has good biocompatibility and can be administered by injection, oral administration,eye,nose, external use and inhalation.
Usually, SBECD can be quickly and completely eliminated from the kidney after administration. In vitro and in vivo acute, subacute and chronic toxicity studies provide safe data and are approved for use in human drug preparations.
The interaction with sulfobutyl-β- cyclodextrin provides a beneficial protective environment for API in its lipophilic cavity, while the hydrophilic surface provides excellent water solubility, solubility and stability.
SBECD is a new type of anionic high soluble cyclodextrin derivatives. It could embed drug molecules to form covalent compounds to increase the drug's stability,solubility,safety.It could reduce the renal toxicity,moderate drug's hemolysis, control the release rate and cover up the bad smell.[hr][u]http://www.cydextrins.com[/u]